Dyslipidemia, Hypertension
Conditions
Brief summary
The purpose of this randomized control trial is to compare the effect of pumpkin seed oil 2g/day with pumpkin seeds given as a dose of 1½ teaspoons/ 4.1 grams a day to provide 2g of lipid (equivalent to 2 grams of oil) on BP (systolic and diastolic), endothelial function, serum lipids, C-reactive protein (CRP) concentrations, and menopausal symptoms in postmenopausal women.
Detailed description
At the onset of menopause CVD rates increase in women. A beneficial effect of pumpkin seed oil on blood pressure has been observed in postmenopausal women. More than 1 in 3 female adults have some form of cardiovascular disease (CVD), which is affected by blood pressure. Pumpkin seed is a good source of phytoestrogens. Phytoestrogens are compounds found in plants and are comparable to human estrogen, capable of producing estrogenic effects. Studies in post menopausal women have demonstrated that pumpkin seed oil, at a dose of 2g per day for 12 weeks can decrease blood pressure and reduce menopausal symptoms.
Interventions
DIETARY_SUPPLEMENTPumpkin seed oil
1 gram capsule of Pumpkin seed oil.
DIETARY_SUPPLEMENTPumpkin seeds
4.1 grams (1½ teaspoons/\ 0.15ounces) of pumpkin seeds
Sponsors
Texas Woman's University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
Yes
Inclusion criteria
* Non-hypertensive with blood pressure less than140/90 mmHg * Post menopausal women or had a bilateral oophorectomy
Exclusion criteria
* Hypotensive women with BP \<90/60 * Taking medications to manage blood pressure and blood lipids * Taking estrogen supplements or on hormone replacement therapy * Taking pumpkin seed oil supplements * Consuming pumpkin seeds more than ¼ cup a month * Diagnosed with depression and taking antidepressants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in systolic and diastolic blood pressure | change measured - baseline and 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Total Cholesterol level (mg/dl) | change measured - baseline and 12 weeks | — |
| Change in Plasma Triglycerides (mg/dl) | change measured - baseline and 12 weeks | — |
| Change in Endothelial Function | change measured - baseline and 12 weeks | Endothelial function will be assessed using a computer based non-invasive peripheral arterial tonometer (Endo-PAT 2000, Itamar Medical Ltd.). |
| Change in Plasma Low-Density Lipoprotein Cholesterol (mg/dl) | change measured - baseline and 12 weeks | — |
| Change in C-reactive protein (CRP) | change measured - baseline and 12 weeks | — |
| Change in Plasma High-Density Lipoprotein Cholesterol (mg/dl) | change measured - baseline and 12 weeks | High-density Lipoprotein-C |
Countries
United States
Outcome results
None listed